Drugs / ASC47
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06972992 | Apr → Sep 2025 | — | Ascletis Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT06427590 | Jul → Dec 2024 | — | Ascletis Pharma Inc | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-11-05 | Ascletis Pharmaceuticals Co., Ltd. | Results 歌礼在2025年肥胖周（ObesityWeek®）报告ASC30口服片Ib期研究的完整分析、ASC30注射剂Ib期研究以及ASC31与ASC47联合用药临床前研究 ascletis.com ↗
Combination of ASC47 and ASC31, a novel peptide agonist targeting both GLP-1R and GIPR, significantly outperformed both tirzepatide and ASC31 monotherapy in promoting weight loss, body fat loss, and muscle preservation in diet-induced obesity (DIO) mouse studies. |
| 2025-10-27 | Ascletis Pharmaceuticals Co., Ltd. | Results 歌礼将携ASC30口服片、ASC30注射剂和ASC31与ASC47联合疗法的研究结果亮相2025年肥胖周（ObesityWeek®） ascletis.com ↗
GLP-1R/GIPR Peptide Agonist ASC31 + ASC47 Shows 119.6% More Weight Loss than Tirzepatide in DIO Mice |
| 2024-12-18 | Ascletis Pharmaceuticals Co., Ltd. | Results Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model ascletis.com ↗ |
| 2024-11-07 | Ascletis Pharmaceuticals Co., Ltd. | Results Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity ascletis.com ↗
Data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated low-density lipoprotein cholesterol (LDL-C) showed that ASC47, via subcutaneous (SQ) injection, demonstrated a half-life of 21 days, supporting once-monthly administration in patients with obesity |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-05 | Ascletis Pharmaceuticals Co., Ltd. | 歌礼在2025年肥胖周（ObesityWeek®）报告ASC30口服片Ib期研究的完整分析、ASC30注射剂Ib期研究以及ASC31与ASC47联合用药临床前研究 ascletis.com ↗ |
| 2025-10-27 | Ascletis Pharmaceuticals Co., Ltd. | 歌礼将携ASC30口服片、ASC30注射剂和ASC31与ASC47联合疗法的研究结果亮相2025年肥胖周（ObesityWeek®） ascletis.com ↗ |
| 2024-12-18 | Ascletis Pharmaceuticals Co., Ltd. | Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model ascletis.com ↗ |
| 2024-11-07 | Ascletis Pharmaceuticals Co., Ltd. | Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity ascletis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASC47 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06972992 ↗ |
| Route | Subcutaneous | “single subcutaneous injection of ASC47” NCT06427590 ↗ |